Vanguard Group Inc Corvus Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,493,357 shares of CRVS stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,493,357
Previous 1,350,633
10.57%
Holding current value
$2.72 Million
Previous $2.38 Million
11.82%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRVS
# of Institutions
51Shares Held
18.3MCall Options Held
29.9KPut Options Held
30.2K-
Orbimed Advisors LLC San Diego, CA6.94MShares$12.6 Million0.28% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$5.96 Million2.56% of portfolio
-
Samlyn Capital, LLC New York, NY2.35MShares$4.27 Million0.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny637KShares$1.16 Million0.0% of portfolio
-
Black Rock Inc. New York, NY523KShares$951,8190.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $84.7M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...